Rituximab induced remission of pemphigus vulgaris: 2 cases;Pemphigus vulgaire évolutif sous corticoïdes et immunosuppresseurs : rémission sous rituximab. Deux observations

Revue de Medecine Interne

Volumn 28, Issue 4, 2007, Pages 266-268

  Borel, C ^a   Launay, F ^a   Garrouste, C ^a   Astudillo, L ^a   Bazex, J ^a   Arlet, P ^a   Paul, C ^a   Viraben, R ^a   Sailler, L ^a  

^a CHU PURPAN   (France)

Author keywords

Anti CD20 monoclonal antibody; Mycophenolate; Pemphigus; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; MULTIPLE CYCLE TREATMENT; PEMPHIGUS VULGARIS; REMISSION; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN INFECTION; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PEMPHIGUS; REMISSION INDUCTION;

EID: 33947691694     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.11.012     Document Type: Article

References (14)

1. Baum S., Scope A., Barzilai A., Azizi E., and Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 548-552
2. Schmidt E., Hunzelmann N., Zillikens D., Brcker E.B., and Goebeler M. Rituximab in refractory auto-immune bullous diseases. Clin. Exp. Dermatol. 31 (2006) 503-508
3. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
4. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., et al. Rituximab for the treatment of refractory auto-immune haemolytic anemia in children. Blood 101 (2003) 3857-3861
5. Manz R.A., Arce S., Cassese G., Hauser A.E., Hiepe F., and Radbruch A. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 14 (2002) 517-521
6. Herti M., Eming R., and Veldman C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest. 116 (2006) 1159-1166
7. Kuwana M., and Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int. J. Hematol. 81 (2005) 106-112
8. Hall A.M., Vickers M.A., McLeod E., and Barker R.N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukaemia by malignant B cells. Blood 105 (2005) 2007-2015
9. Miller C., Stedra J., Kelsoe G., and Cerny J. Facultative role of germinal centers and T cells in the somatic diversification of IgVH genes. J. Exp. Med. 181 (1995) 1319-1331
10. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J. Am. Acad. Dermatol. 51 (2004) 817-819
11. Barnadas M., Roe E., Brunet S., Garcia P., Bergua P., Pimentel L., et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 69-74
12. Basse G., Ribes D., Kamar N., Mehrenberger M., Esposito L., Guitard J., et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 80 (2005) 1560-1564
13. Sera T., Hiasa Y., Michitaka K., Konishi I., Matsuura K., Tokumoto Y., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern. Med. 45 (2006) 721-724
14. Sailler L., Attané A., Beyne-Rauzy O., Blancher A., Canonge J.M., Pourrat J., et al. Étude de l'utilisation du rituximab dans les maladies médiées par des autoanticorps pathogènes : un effet thérapeutique certain, des effets secondaires sous-estimés ? Étude rétrospective sur deux ans au CHU de Toulouse. Rev. Med. Int. 27 S2 (2006) S107